EAGAN, Minn.--(BUSINESS WIRE)--A phase 1b clinical trial at the University of Illinois at Chicago (UIC) will evaluate a new combination therapy for advanced pancreatic cancer that includes two Biothera cancer immunotherapy drug candidates.
This phase 1b open-label dose escalation study will evaluate weekly treatment with BTH1704 at assigned doses (3, 6 or 9 mg/kg) and Imprime PGG 4 mg/kg, in combination with gemcitabine 1000 mg/m2 administered on days 1, 8, and 15 of each 28-day cycle, in up to 24 patients with locally advanced, recurrent or metastatic PDAC. The primary objective of the study is to determine the maximum administered dose of BTH1704 in combination with gemcitabine and Imprime PGG when given to patients with advanced and previously treated PDAC. Secondary objectives are to evaluate clinical response, time to progression, progression-free survival and overall survival. For more information on this trial, please visit http://clinicaltrials.gov using the identifier NCT 02132403.
Imprime PGG is a novel innate immune cell modulator, consisting of soluble beta-1,3/1,6 glucan derived from a proprietary strain of yeast, that engages neutrophils, monocytes and macrophages in anti-tumor activity against complement opsonized tumor cells. In phase 2 clinical trials, Imprime PGG has been associated with objective tumor responses in multiple clinical trials for non-small cell lung cancer (NSCLC), colorectal cancer and chronic lymphocytic leukemia. Imprime PGG is currently being investigated in a phase 3 clinical trial for advanced colorectal cancer and in phase 2 studies for NSCLC, Non-Hodgkin lymphoma and pancreas cancer.
Biothera is a U.S. biotechnology company dedicated to improving immune health. The company is a pioneer in the field of cancer immunotherapy and the leader in innate immune modulation. More information is available at www.biothera.com/pharma or follow us on Twitter.
Cancer Research Technology (CRT) is a specialist commercialisation and development company, which aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies. CRT is a wholly owned subsidiary of Cancer Research UK, the world’s leading cancer charity dedicated to saving lives through research. Further information about CRT can be found at www.cancertechnology.com.
About Cancer Research UK
* Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research.
* Cancer Research UK’s pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
* Cancer Research UK receives no government funding for its life-saving research. Every step it makes towards beating cancer relies on every pound donated.
* Cancer Research UK has been at the heart of the progress that has already seen survival rates in the UK double in the last forty years.
* Today, 2 in 4 people survive cancer. Cancer Research UK’s ambition is to accelerate progress so that 3 in 4 people will survive cancer within the next 20 years.
* Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
* Together with its partners and supporters, Cancer Research UK’s vision is to bring forward the day when all cancers are cured.
For further information about Cancer Research UK’s work or to find out how to support the charity, please call 0300 123 1022 or visit www.cancerresearchuk.org. Follow us on Twitter and Facebook.
Contacts
Biothera, the Immune Health Company
David Walsh, 651-256-4606
SVP Marketing & Communications
dwalsh@biothera.com
or
Cancer Research Technology
Ailsa Stevens or Emma Rigby
+44 (0) 20 3469 8300
After hours:
Duty Press Officer on 07050 264 059
Help employers find you! Check out all the jobs and post your resume.
